PHASE II EVALUATION OF TOPOTECAN IN PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS

拓扑替康治疗儿科中枢神经系统肿瘤的 II 期评估

• 批准号: 3764432
• 负责人: PETER PHILLIPS
• 金额: --
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3764432
• 关键词: DNA topoisomerases; antineoplastics; central nervous system neoplasms; clinical trials; enzyme inhibitors; human subject; human therapy evaluation; neoplasm /cancer pharmacology; pediatric neoplasm /cancer; pediatric pharmacology

The purposes of this study are to determine the objective response rate and evaluate the steady state blood and CSF levels of the active metabolites of topotecan,an anticancer agent being studied in phase II trials. Knowledge of drug concentrations will permit us to optimize treatment schedules and knowledge of the response rate will allow us to know if this agent should be included in phase III survival studies.

本研究的目的是确定客观反应率 并评估活性成分的稳态血液和CSF水平 拓扑替康的代谢物，一种正在研究的II期抗癌药 审判药物浓度的知识将使我们能够优化 治疗时间表和反应率的知识将使我们能够 知道这种药物是否应该包括在III期生存研究中。